Banced Has Upped Snap On (SNA) Position; Therapeuticsmd (TXMD) Stock Price Declined While 1492 Capital Management Increased Its Holding

February 15, 2018 - By Kurt Siggers

Banced Corp increased its stake in Snap On Inc (SNA) by 111.12% based on its latest 2017Q3 regulatory filing with the SEC. Banced Corp bought 2,238 shares as the company’s stock declined 3.98% while stock markets rallied. The institutional investor held 4,252 shares of the industrial machinery and components company at the end of 2017Q3, valued at $634,000, up from 2,014 at the end of the previous reported quarter. Banced Corp who had been investing in Snap On Inc for a number of months, seems to be bullish on the $9.09B market cap company. The stock increased 0.26% or $0.41 during the last trading session, reaching $159.44. About 91,351 shares traded. Snap-on Incorporated (NYSE:SNA) has risen 2.47% since February 15, 2017 and is uptrending. It has underperformed by 14.23% the S&P500.

1492 Capital Management Llc increased its stake in Therapeuticsmd Inc (TXMD) by 86.42% based on its latest 2017Q3 regulatory filing with the SEC. 1492 Capital Management Llc bought 181,115 shares as the company’s stock declined 24.96% while stock markets rallied. The institutional investor held 390,702 shares of the health care company at the end of 2017Q3, valued at $2.07M, up from 209,587 at the end of the previous reported quarter. 1492 Capital Management Llc who had been investing in Therapeuticsmd Inc for a number of months, seems to be bullish on the $1.16 billion market cap company. The stock decreased 2.10% or $0.115 during the last trading session, reaching $5.355. About 473,450 shares traded. TherapeuticsMD, Inc. (NYSEMKT:TXMD) has declined 46.30% since February 15, 2017 and is downtrending. It has underperformed by 63.00% the S&P500.

Investors sentiment increased to 1.73 in Q3 2017. Its up 0.69, from 1.04 in 2017Q2. It improved, as 9 investors sold TXMD shares while 28 reduced holdings. 24 funds opened positions while 40 raised stakes. 162.04 million shares or 5.51% more from 153.57 million shares in 2017Q2 were reported. Omers Administration Corp accumulated 0% or 34,900 shares. Edge Wealth Mngmt has invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). State Of Wisconsin Board reported 113,000 shares. Outfitter Advsr Limited has invested 0.1% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Nationwide Fund Advisors has invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Raymond James Fin Services Advsr Inc holds 0% or 142,930 shares in its portfolio. Hanson Mcclain holds 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD) or 500 shares. Amalgamated Commercial Bank holds 0% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 19,940 shares. Eqis Capital Mgmt Inc invested in 0% or 14,864 shares. Sta Wealth Mgmt Lc holds 0.03% or 13,873 shares. Aperio Group Inc Limited Liability Corporation holds 34,227 shares or 0% of its portfolio. Parametric Portfolio Associate Limited Liability invested in 0% or 32,485 shares. Cubist Systematic Strategies Limited Liability Company reported 10,340 shares. Moreover, Swiss Bank & Trust has 0% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 289,800 shares. Legal & General Gp Public Limited Company reported 0% stake.

Among 4 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TherapeuticsMD had 6 analyst reports since September 21, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $15.0 target in Monday, September 21 report. Oppenheimer initiated the stock with “Outperform” rating in Tuesday, November 22 report. The stock of TherapeuticsMD, Inc. (NASDAQ:TXMD) earned “Buy” rating by Jefferies on Tuesday, December 8. The rating was reinitiated by Jefferies on Tuesday, November 22 with “Buy”. As per Tuesday, December 8, the company rating was maintained by Stifel Nicolaus.

Among 10 analysts covering Snap-on (NYSE:SNA), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Snap-on had 29 analyst reports since August 20, 2015 according to SRatingsIntel. The rating was downgraded by Longbow on Monday, August 21 to “Neutral”. The stock has “Buy” rating by Robert W. Baird on Tuesday, August 1. The firm has “Buy” rating by Oppenheimer given on Sunday, June 11. Jefferies maintained it with “Hold” rating and $175.0 target in Friday, November 3 report. The stock has “Buy” rating by Northcoast on Friday, February 9. The company was maintained on Thursday, April 13 by IBC. Robert W. Baird maintained it with “Buy” rating and $220.0 target in Monday, January 29 report. As per Thursday, February 8, the company rating was maintained by Robert W. Baird. The firm has “Buy” rating by FBR Capital given on Friday, July 21. The company was initiated on Tuesday, October 20 by Jefferies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: